文献速递皮肤肿瘤

原发诊断至首次远处复发时间与转移性黑色素瘤进展及生存的关联

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
PubMed 文献 · JAMA Dermatol · 2019-01-01

本研究基于法国多中心前瞻性MelBase队列,纳入638例不可切除III/IV期黑色素瘤成人患者,评估原发灶切除至首次远处复发时间与无进展生存期及总生存期的关联。结果显示,无论将复发时间作为连续变量还是分类变量(<12个月、12-24个月、>24个月),均未发现其与无进展生存期或总生存期存在显著关联,分层分析后结果仍不显著。

要点

  • 复发时间与PFS无关:连续变量HR 0.99(95%CI 0.99-1.01)
  • 复发时间与OS无关:连续变量HR 0.99(95%CI 0.98-1.02)
  • 按治疗分层后,复发时间与PFS及OS的关联仍不显著

核心结论

  • 在MelBase队列中,转移性黑色素瘤的复发时间与无进展生存期或总生存期均无显著关联。

研究设计与样本

  • 研究于2013年3月1日至2017年9月1日进行,纳入法国多中心前瞻性MelBase队列中638例不可切除III期或IV期黑色素瘤成人患者。
  • 纳入接受一线免疫治疗、靶向治疗或化疗的患者,排除原发灶不明或新发转移性黑色素瘤患者。
  • 数据分析时间为2013年3月1日至2017年12月1日,采用Cox比例风险回归模型评估关联。

主要发现

  • 共纳入638例患者(272例女性,366例男性;中位年龄64岁,四分位距52-73岁)。
  • 原发灶切除至首次远处复发的中位时间为25个月(四分位距12-55个月)。
  • 复发时间作为连续变量与PFS无关联(HR 0.99;95%CI 0.99-1.01),分类变量亦无关联(12-24个月:HR 0.75;95%CI 0.56-1.02;>24个月:HR 0.62;95%CI 0.47-1.01)。
  • 复发时间作为连续变量与OS无关联(HR 0.99;95%CI 0.98-1.02),分类变量亦无关联(12-24个月:HR 0.76;95%CI 0.54-1.07;>24个月:HR 0.61;95%CI 0.54-1.03)。
  • 按治疗分层后,上述结果仍不显著。

临床怎么用

  • 对于不可切除III/IV期黑色素瘤患者,原发灶切除至首次远处复发的时间不宜作为预测PFS或OS的独立指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The prognosis of advanced melanoma has been greatly improved by new therapeutic agents and clinicians rely on dynamic signals to drive their therapeutic choices. Although the kinetics of metastatic disease seem to be correlated with survival, progression of the localized disease is not predictable. OBJECTIVE: To assess whether progression of metastatic disease is associated with the time to the first distant recurrence of melanoma. DESIGN, SETTING, AND PARTICIPANTS: This study was conducted from March 1, 2013, to September 1, 2017, among 638 adults with unresectable stage III or IV melanoma within the French multicentric prospective cohort MelBase. Patients treated with first-line immunotherapies, targeted therapies, or chemotherapy were included. Patients with unknown primary or de novo metastatic melanoma were not included. Data were analyzed from March 1, 2013, to December 1, 2017. MAIN OUTCOMES AND MEASURES: The date of primary excision and time to first distant recurrence, progression-free survival, and overall survival were collected. Cox proportional hazards regression models were planned to assess the association between time to first distant recurrence and progression-free survival or overall survival, which was evaluated in terms of hazard ratio (HR). Time to recurrence was analyzed both as a continuous and categorical variable (<12 months, 12-24 months, and >24 months). RESULTS: A total of 638 patients (272 women and 366 men; median age, 64 years [interquartile range, 52-73 years]) were included in the study. The median time from primary excision to first distant recurrence was 25 months (interquartile range, 12-55 months). There was no evidence of association of the time to recurrence with progression-free survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.99-1.01) or after categorization (12-24 months: HR, 0.75; 95% CI, 0.56-1.02; >24 months: HR, 0.62; 95% CI; 0.47-1.01). There was no evidence of association of the time to recurrence with overall survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.98-1.02) or after categorization (12-24 months: HR, 0.76; 95% CI, 0.54-1.07; >24 months: HR, 0.61; 95% CI, 0.54-1.03). Those results remained nonsignificant after stratification by treatment. CONCLUSIONS AND RELEVANCE: In the MelBase cohort, time to recurrence of metastatic melanoma appears not to be associated with progression-free survival or overall survival.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Vallet A, Oriano B, Mortier L, et al. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. JAMA Dermatol. 2019. PMID: 31042256. doi:10.1001/jamadermatol.2019.0425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。